MedTrace Logo

Surgery for Masaoka-Koga I-II Thymoma

NCT05001113 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2022-09-19

No results posted yet for this study

Summary

The purpose of this study was to evaluate the safety and perioperative outcomes of the subxiphoid approach versus the lateral intercostal approach thoracoscopic thymectomy for Masaoka-Koga I-II thymoma.

Conditions

  • Thymoma
  • Masaoka Stage I
  • Masaoka Stage II

Interventions

PROCEDURE

the subxiphoid approach thoracoscopic thymectomy

A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.

PROCEDURE

the lateral intercostal approach thoracoscopic thymectomy

Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces. Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.

Sponsors & Collaborators

  • Zhongshan Hospital (Xiamen), Fudan University

    collaborator OTHER

  • Xuhui Central Hospital, Shanghai

    collaborator OTHER

  • Shanghai Minhang Central Hospital

    collaborator OTHER

  • Shanghai Qingpu Central Hospital

    collaborator UNKNOWN

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Lijie Tan, MD · Shanghai Zhongshan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-15
Primary Completion
2022-02-15
Completion
2022-08-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001113 on ClinicalTrials.gov